High Cortisol Does Not Just Kill Desire After 40. New Research Links It to Alzheimer’s Risk in Women.

Medicine has been measuring the wrong thing, at the wrong time of day, while three systems quietly went offline.

Welcome to The Female Edge. Today we dive into the problem of stress and cortisol, including why you want to know your level and why your doctor will fight with you about ordering it.

Your doctor did not run a cortisol test. Your doctor ran a complete blood count, maybe a thyroid panel, possibly a lipid panel if you were due, and then looked up from the computer and said you looked great.

You did not feel great.

You felt like someone had unplugged you from the wall three years ago and you have been running on backup battery ever since. You are waking at 4 AM with your heart already racing, dragging yourself through noon on caffeine and blind optimism, staring at the ceiling at midnight wondering what happened to the woman who used to sleep like a normal person.

You are watching something in you — your drive, desire, patience, words — slowly drain out.

The testing was incomplete. Cortisol was never on the order, and not because your doctor is negligent. Most are genuinely trying. But standard primary care was not built to catch a rhythm problem, it was built to catch a crisis. You are not in crisis. You are just slowly coming undone in a way that does not show up on a standard lab panel.

Here is what no one measured: what your cortisol is doing throughout the day. When you wake up, noon, at 4 PM, at 10 PM. No one asked whether you have spent the last decade running too hot in the morning, completely flat by afternoon, and inexplicably wired at midnight, which is the exact opposite of what a human body is designed to do. Your doctor doesn’t test cortisol because he doesn’t believe in adrenal fatigue. No one connected that pattern to the three systems you already know from this publication: the alarm system, the bonding circuitry, the yes-to-life system.

And no one told you what that same pattern is now doing to your brain.

New research links disrupted cortisol rhythm, not just high cortisol but cortisol arriving at the wrong levels at the wrong hours of the day, to measurable structural changes in the brain and elevated Alzheimer’s risk in women.

Medicine looked at everything except the thing that explained it all.

The file was never opened.

The Condition Your Doctor Does Not Believe In

The words for what you are feeling, in the language available to you, might be “adrenal fatigue.”

Your doctor does not believe in adrenal fatigue. They are right not to. As a clinical entity with a billing code, a diagnostic threshold, and a measurable end-organ failure… adrenal fatigue does not exist.¹ Your doctor does not believe in adrenal fatigue. They are right not to. As a clinical entity — with a billing code, a diagnostic threshold, and a measurable end-organ failure — adrenal fatigue does not exist.¹ The Endocrine Society has said so explicitly, as have The American Association of Clinical Endocrinologists, and the American College of Endocrinology. Mainstream endocrinology has been saying so for decades. They are not being dismissive, they are being technically correct based on their longstanding opinion and conceptual model.

What this technical correctness misses is that the term is reaching for something real. The disrupted sleep, the noon collapse, the second wind at 10 PM — none of it is produced by adrenal glands that have failed due to autoimmune attack, as we see in Addison disease. It is produced by a cortisol rhythm that has gone off the rails. The clinical signal is HPA axis dysregulation: documented across thousands of papers, mappable on a salivary or urinary cortisol curve, and almost never assessed in standard primary care.

The reason women searching for what is wrong arrive at “adrenal fatigue” is that the medical conversation has handed them no other words. Endocrinology declined the lay term and then did not replace it with the accurate one, so the language available gets dismissed while the underlying biology gets to keep running. The biology is measurable, mappable, and as we will explore, increasingly tied to brain, libido, and metabolic outcomes.

This is the gap many women face. Your doctor isn't wrong, they're just done with the conversation about two sentences too early.

The Test That Misses the Point

To see what is missing in the lab work, you need to understand what a cortisol test is — and how rarely one gets ordered.

A serum cortisol is a single blood draw, usually at 8 AM, measuring cortisol at one moment in time. It is the simple, decades-old test, designed to catch the two ends of adrenal failure: a level high enough to suggest Cushing’s syndrome, or low enough to suggest Addison’s disease. Neither is what most women in their 40s have. Primary care does not order this test unless adrenal pathology is already suspected. A fatigued, sleep-disrupted woman in midlife does not register as adrenal pathology, so the single cortisol almost never appears on the order.

A cortisol diurnal pattern is a different test entirely. It is four to six measurements taken across the day, at the morning peak, noon, afternoon, evening, bedtime. It is usually run in saliva (a quick swab, no needle, or tube of collected saliva) or in dried urine collected over 24 hours. It does not measure the level of your cortisol. It measures the shape of the cortisol pattern, whether the morning peak is there, whether the afternoon descent happens, whether the system goes quiet at night when you are supposed to sleep. This is the test that captures the thing actually going wrong. It is also a test most primary care doctors have never ordered.

So the standard of care is not the wrong test, it is no test at all. A morning serum cortisol would tell you whether your adrenal glands are catastrophically failing, which is not the question. A diurnal pattern would tell you whether your cortisol rhythm has been distorted by years of sustained threat exposure that your body recorded and your doctor did not. That is the question. Most women get neither.

The relevant question is not whether your cortisol is high at 8 AM. It is whether it is still elevated at midnight. Whether it is flat when it should have a peak. Whether the rhythm that governs your immune response, your hormonal output, your capacity for attachment, and your brain’s energy supply has gone off the rails — and no one has looked.

A single number answers none of those questions. Most of the time, no number gets ordered at all.

What the Alarm System Does to All Three Systems

In the last Female Edge essay, I described three systems and the hierarchy between them. The alarm system, i.e., the HPA axis, sits at the top. When it runs dysregulated, it does not just affect stress response. It actively suppresses what sits below it.

The HPG axis, the yes-to-life system governing estrogen, progesterone, and testosterone, sits downstream. Chronic alarm suppresses HPG output in a form of ancient triage. A body under threat is not designed to reproduce, to desire, or to reach for things.

The oxytocin-vasopressin system — the bonding circuitry — also sits downstream. It runs on safety, on skin, on the slow nervous-system handshake mammals do when they trust each other. It does not function in a body that is bracing. The Coan hand-holding data established this with measurable neural signatures: a chronically activated alarm system produces something close to the biomarker profile of chronic low-grade threat, even when the relationship is loving.

This is the mechanism behind flattened desire, disconnection from a partner she still loves, and the immune dysregulation that follows from years of the alarm running the hierarchy. Most women are told their hormones are normal. Their cortisol rhythm is not measured. The bonding circuitry is not assessed. The conversation ends at the blood draw.

What a 2024 Study Just Added to This Picture

The three-system hierarchy I have been describing in this series has a fourth downstream consequence that 2024 research now makes legible.

Mosconi and colleagues, publishing in Scientific Reports in March 2024, examined sex-specific associations between serum cortisol and brain biomarkers of Alzheimer’s risk. The findings in women are specific enough to require a direct statement.

In women, high cortisol was linked to two specific brain changes more strongly than it was in men. One was more buildup of the amyloid plaques that show up in Alzheimer’s brains. The other was less glucose being burned for fuel in the front of the brain, the part that handles decision-making, planning, and judgment. That second change, the fuel problem, was worse in women who had already gone through menopause than in women who had not.

In women, high cortisol was linked to more Alzheimer’s plaque and to less glucose being used in the front of the brain… and the glucose problem hit harder after menopause.

The brain is downstream of the alarm system too.

And it is not the only downstream signature now well-mapped. Higher midlife cortisol has been linked to poorer memory and smaller cerebral brain volume, with stronger effects in women;² to HPA hyperactivity across the major depression literature;³ and to the insulin resistance, visceral adiposity, and abnormal glucose pattern that travel with a chronically distorted cortisol rhythm.⁴

The mechanism is known. Estrogen supports cerebral glucose metabolism. As estrogen declines, potentially suppressed first by the alarm hierarchy and then by menopause itself, the brain’s metabolic efficiency becomes more dependent on the hormonal and stress environment surrounding it. A postmenopausal woman with a dysregulated cortisol rhythm is not just carrying a stress burden, she is carrying a cortisol environment that the 2024 data associates with the specific brain biomarkers that precede Alzheimer’s diagnosis by decades.

So sit with this.

The mainstream physician would not run the test. Next they are missing the brain data. So the same dysregulated rhythm that medicine refused to measure is showing up on the brain scans of women who will get a very different diagnosis at 65 or 70.

How many women are sitting in their kitchen at 4 AM right now, running on backup battery, being told they look great and labs are fine? How long does the conversation take to catch up?

The findings exist but the conversation does not, which means it must start with you.

The Autoimmune Connection

Women carry approximately 80 percent of the autoimmune disease burden.⁵ Hashimoto’s thyroiditis, lupus, rheumatoid arthritis, multiple sclerosis — all present with disproportionate female prevalence. The explanation that gets the least clinical airtime is the most physiologically direct one.

Women show greater HPA reactivity specifically to social rejection and interpersonal stressors, while men show greater reactivity to achievement challenges — a stressor-type-by-sex interaction documented across multiple study populations, though not uniformly replicated when menstrual cycle phase is rigorously controlled.⁶ The texture of a typical woman’s life is precisely the category of stressor that the female alarm system is most sensitized to, including the relational scanning, the mental load, the chronic awareness of being evaluated on multiple dimensions simultaneously.

Cortisol dysregulation does not just suppress sex hormone output. It alters immune regulation. A chronically dysregulated cortisol rhythm produces immune system behavior that predisposes inflammatory and autoimmune patterns.

That these two facts — autoimmune disease disproportionately affects women, and the female HPA axis is disproportionately reactive to the specific stressors women chronically carry — are rarely presented together in a clinical conversation. That is a failure of synthesis, not a gap in the data.

What’s Next in Our Series

Say you get a cortisol test performed. Your doctor says it’s normal. What happens next?

That’s what we will explore.

The cortisol–brain signal does not land equally on every woman. Postmenopausal status amplifies it. UK Biobank data show total brain volume loss running roughly four times steeper after the menopausal transition. APOE ε4 carriage amplifies it further. One dataset puts the combined effect of high cortisol and two ε4 alleles at the equivalent of more than three decades of cognitive aging.

The convergence of menopausal status, APOE ε4 carriage, and a dysregulated cortisol rhythm produces a vulnerability hierarchy that most clinical panels do not yet measure and most clinical conversations do not yet name.

The next post unpacks that hierarchy: which populations of women carry the steepest cortisol–cognition trajectory, what the APOE ε4 convergence actually does, what to measure and how to interpret the results, and why menopausal status is the inflection point most clinicians miss.

Let me know if you have questions. I am keeping them open to all for the first 24 hours. I will read all of them as I write the next post.

Thank you for being here and reading my work.

Endnotes

1. The clinical non-status of adrenal fatigue

Arnold MJ. Off-label use and misuse of hormone supplements: AACE and ACE position statement. Am Fam Physician. 2020. PMID: 33320505. The American Association of Clinical Endocrinologists and American College of Endocrinology state explicitly that adrenal fatigue is “a condition not recognized by endocrinology specialists,” that the tests proposed to diagnose it “have not been well studied to develop reference standards,” and that treatment risks masking the diagnosis of adrenal insufficiency or other endocrine disorders. The statement also flags that “adrenal support” supplements may contain undisclosed thyroid and steroid hormones.

Cadegiani FA, et al. Adrenal fatigue does not exist: a systematic review. BMC Endocr Disord. 2016;16(1):48. doi: 10.1186/s12902-016-0128-4. PMID: 27557747. Systematic review of 58 studies drawn from 3,470 articles concluding there is no substantiation that adrenal fatigue is an actual medical condition. The symptom cluster patients describe is real and heterogeneous; what it points to clinically is HPA axis dysregulation — measurable on a salivary or urinary cortisol curve, not on a single serum draw. Mainstream endocrinology distinguishes adrenal fatigue (lay term, no clinical entity) from adrenal insufficiency (Addison’s disease, clinical entity with measurable adrenal failure).

Bornstein SR, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016. The formal guideline addresses primary, secondary, and tertiary adrenal insufficiency exclusively. Adrenal fatigue is not mentioned — an omission consistent with the Endocrine Society’s patient-facing position that no scientific proof supports adrenal fatigue as a true medical condition.

Cardillo G. Beyond adrenal fatigue: reframing the Adrenal Stress Index through neutrophil-mediated glucocorticoid resistance. Front Endocrinol. 2026. Recent reframing attempt that, even while proposing the Adrenal Stress Index as a research tool, explicitly acknowledges the concept is dismissed by mainstream endocrinology and moves away from the term “adrenal fatigue.”

Vaidya A, et al. Adrenal insufficiency in adults. JAMA. 2025. Recent JAMA review of adrenal insufficiency in adults makes no mention of adrenal fatigue as a diagnostic entity, recognizing only primary, secondary, and glucocorticoid-induced adrenal insufficiency as legitimate diagnoses.

2. Sex-specific effects of memory and cerebral volume

Echouffo-Tcheugui JB, et al. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. Neurology. 2018;91(21):e1961–e1970. PMID: 30355700. In 2,231 dementia-free adults (mean age 48.5), higher cortisol was associated with worse memory, lower total cerebral brain volume, and reduced frontal and occipital gray matter. The cerebral volume association showed a significant sex interaction (p = 0.048) — inverse in women (p = 0.001), null in men (p = 0.717).

Dronse J, et al. Serum cortisol is negatively related to hippocampal volume, brain structure, and memory performance in healthy aging and Alzheimer’s disease. Front Aging Neurosci. 2023. Higher serum cortisol negatively correlated with hippocampal volume and indirectly linked to worse memory through hippocampal volume reduction.

Resmini E, et al. Verbal and visual memory performance and hippocampal volumes in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012. Reduced hippocampal volume and impaired verbal/visual memory in Cushing’s.

Papakokkinou E, et al. Functional brain alterations in Cushing’s syndrome. Front Endocrinol. 2023. Review of structural and functional brain changes — reduced hippocampal, amygdala, and prefrontal volumes.

Piasecka M, et al. Psychiatric and neurocognitive consequences of endogenous hypercortisolism. J Intern Med. 2020. Cognitive deficits in episodic and working memory, executive function, and attention persist even after biochemical cure.

Nieman LK, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015. Long-term remission patients still perform significantly worse on executive function and memory testing versus matched controls.

3. HPA hyperactivity in depression with sex-specific patterns and subtype caveats

Stetler C, et al. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73(2):114–126. PMID: 21257974. Meta-analytic confirmation of HPA hyperactivity in MDD across multiple sampling methods; largest effects in inpatient and melancholic samples.

Wang R, et al. Sex differences in cortisol levels in depression: a systematic review and meta-analysis. Front Neuroendocrinol. 2024. Depressed women had higher hair cortisol, higher cortisol awakening response, and higher evening basal cortisol than sex-matched healthy controls — and a different cortisol stress-reactivity profile than depressed men.

Geoffroy MC, et al. Prospective association of morning salivary cortisol with depressive symptoms in mid-life: a life-course study. PLoS One. 2013. In a British birth cohort, higher late-morning cortisol at age 45 predicted depressive symptoms at age 50 in women.

Iliadis SI, et al. Prenatal and postpartum evening salivary cortisol levels in association with peripartum depressive symptoms. PLoS One. 2015. Higher evening salivary cortisol associated with postpartum depressive symptoms (OR = 4.1 per cortisol increase), independent of history of depression, tobacco, partner support, breastfeeding, life stressors, and sleep.

Nandam LS, et al. Cortisol and major depressive disorder — translating findings from humans to animal models and back. Front Psychiatry. 2020. Elevated cortisol stress-response is associated with acute and severe forms of MDD, but not mild or atypical forms — the relationship is subtype-dependent.

Malhi GS, et al. Depression. Lancet. 2018. HPA hyperactivity is one of the most consistent biological findings in severe melancholic depression, driven by excessive stress-related cortisol release and impaired glucocorticoid receptor feedback.

Guerrieri GM, et al. The cortisol and ACTH response to Dex/CRH testing in women with and without perimenopausal depression. J Clin Endocrinol Metab. 2021. Null finding worth flagging: no differences in baseline or stimulated cortisol between perimenopausal women with and without depression — perimenopausal depression may not be uniformly HPA-driven.

4. Cortisol and metabolic dysfunction: observational evidence with a causality caveat

Anagnostis P, et al. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692–2701. PMID: 19470627. Mechanisms: cortisol drives hepatic gluconeogenesis, antagonizes insulin action, promotes visceral fat. Proposes “functional hypercortisolism” via 11β-HSD1 amplification in adipose tissue and liver.

Kuckuck S, et al. Long-term glucocorticoids in relation to the metabolic syndrome and cardiovascular disease: a systematic review and meta-analysis. J Intern Med. 2024. Hair cortisol consistently associated with cardiovascular disease presence (SMD = 0.48, 95% CI 0.16–0.79), largely independent of standard risk factors.

Kuckuck S, et al. Hair cortisone levels and the metabolic syndrome: stronger links in younger compared to older adults. J Clin Endocrinol Metab. 2025. In n = 1,405, hair cortisol and cortisone were positively associated with metabolic syndrome (OR 1.27 and 1.32), waist circumference, and triglycerides — stronger effects in younger adults.

Pivonello R, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016. In Cushing’s: glucose metabolism impaired in 14–74%, diabetes 21–47%, hypertension 37–82%, dyslipidemia 40–70%.

Miller BS, et al. Evaluation and treatment of patients with hypercortisolism: a review. JAMA Surg. 2020. Clinical review of hypercortisolism diagnosis and metabolic sequelae.

Januszewicz A, et al. Cardiac phenotypes in secondary hypertension: JACC state-of-the-art review. J Am Coll Cardiol.2022. Cardiac structural and functional phenotypes in cortisol-driven hypertension.

Kwok MK, et al. The role of cortisol in ischemic heart disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional Mendelian randomization study. BMC Med. 2020. Null finding: genetically predicted cortisol was not associated with ischemic heart disease, stroke, T2D, or cardiovascular risk factors, raising the question of whether observational associations reflect causation or confounding.

5. Autoimmune disease burden in women

Fairweather D, et al. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol.2008;173(3):600–609. Foundational figure: autoimmune diseases affect approximately 8% of the population, and 78% of those affected are women. The “~80 percent” framing rounds this treatment-burden statistic.

Conrad N, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023. Across 19 autoimmune conditions, 63.9% of new diagnoses were in women — a lower figure than the Fairweather, et al. treatment statistic because incidence and treatment burden track differently.

Bustillos CG, et al. Sex matters: hormonal and chromosomal determinants of autoimmunity and anti-cancer immunity across the lifespan. Immunol Rev. 2026. Recent review reaffirms that approximately 80% of patients treated for autoimmunity are women; the gap between ~64% incidence and ~78–80% treatment burden reflects the chronic, treatment-intensive nature of female-predominant conditions (thyroiditis, SLE, Sjögren’s, scleroderma).

6. Sex differences in HPA reactivity to social and interpersonal stressors — with cycle-phase and methodological caveats

Stroud LR, et al. Sex differences in stress responses: social rejection versus achievement stress. Biol Psychiatry.2002. Documented the stressor-type-by-sex interaction this post relies on: women showed significantly greater cortisol responses to social rejection challenges; men showed greater responses to achievement challenges. The effect is stressor-specific, not blanket female hyperreactivity.

Dickerson SS, et al. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull. 2004. Meta-analysis of 208 studies establishing social-evaluative threat as the strongest cortisol elicitor (d = 0.67) versus non-evaluative tasks (d = 0.21). Establishes the mechanism behind the stressor-type effect Stroud documented, though the meta-analysis itself did not find a strong overall sex difference when stressor type was not differentiated.

Wadiwalla M, et al. Effects of manipulating the amount of social-evaluative threat on the cortisol stress response in young healthy women. Stress. 2010. In women specifically, manipulating social-evaluative threat (but not cognitive load) significantly affected cortisol responses.

Oldehinkel AJ, et al. Sensitivity to the depressogenic effect of stress and HPA-axis reactivity in adolescence: a review of gender differences. Neurosci Biobehav Rev. 2011. Adolescent girls show greater sensitivity specifically to interpersonal stressors — a developmental signal that may contribute to higher depression rates in females.

Merz CJ, et al. Sex differences in stress effects on emotional learning. J Neurosci Res. 2017. Review of how sex modifies stress and cortisol effects on emotional processing and learning.

Stephens MA, et al. Hypothalamic-pituitary-adrenal axis response to acute psychosocial stress: effects of biological sex and circulating sex hormones. Psychoneuroendocrinology. 2016. Caveat worth flagging: in the largest TSST study to date (n = 282), men had greater ACTH and cortisol responses than women in the follicular phase — menstrual cycle phase materially modifies the sex comparison.

Poppelaars ES, et al. Social-evaluative threat: stress response stages and influences of biological sex and neuroticism. Psychoneuroendocrinology. 2019. Caveat worth flagging: when menstrual cycle phase and neuroticism were rigorously controlled, no sex differences in HPA reactivity to social-evaluative threat emerged — suggesting some of the published sex effect may be confounded by uncontrolled hormonal state.